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INTRODUCTION 
Cardiovascular diseases are the most common 
cause of morbidity and mortality in the United States. 
Remarkable growth has occurred in the medical 
community regarding the recognition, understand- 
ing, and treatment of these diseases. This growth has 
been skewed, however, because most of the available 
resources have been directed toward the diagnosis 
and therapy of coronary artery disease. The impact 
that peripheral vascular diseases have on our national 
health is now receiving increased attention, but it is 
critical that strategies for the prevention, diagnosis, 
and treatment of these diseases be improved. 
Peripheral vascular diseases (noncardiac ircula- 
tory disorders) are highly prevalent in the United 
States. For example, peripheral arterial disease (PAD) 
affects 10% to 12% of the adult population. 1,2 Ap- 
proximately one third of persons with PAD have 
clinically significant symptoms in their legs (e.g., 
claudication, rest pain, or nonhealing wounds) that 
severely impair daily walldng, ambulatory activities, 
and vocation. ~-s Thus PAD is a major cause of 
disability in the United States. Despite the association 
of peripheral atherosclerosis with a markedly in- 
creased risk of cardiovascular mortality, there is little 
awareness of the pathogencsis, natural history, and 
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management of this disease among practicing physi- 
cians until severe symptoms supervene. 6 
Cerebrovascular diseases (stroke and transient 
ischemic attack) are also leading causes of morbidity 
and mortality. 7,s Major advances have been made in 
the noninvasive evaluation ofcerebrovascular disease 
with duplex ultrasound and other techniques of 
imaging. 9Recent clinical investigations have unam- 
biguously demonstrated the relative benefits of sur- 
gical and medical therapeutic approaches for both 
symptomatic and asymptomatic carotid artery dis- 
ease. l°,n Information regarding new diagnostic tech- 
niques and the findings from clinical trials must be 
well disseminated to the general medical community 
to optimize the potential benefits of early inter- 
vcnt ion.  
Deep vein thrombosis and pulmonary embolism 
(symptomatic and asymptomatic) are present in more 
than 750,000 individuals annually and results in 
significant immediate morbidity and mortality. 12 In 
addition to the acute sequelae, patients who have deep 
vein thrombosis are at risk for postthrombotic syn- 
drome (limb edema, swelling, and stasis ulceration), 
which is associated' with restricted ambulatory func- 
tion and disability. 13 The early detection of venous 
thrombosis i enhanced by duplex ultrasound. 14An 
increasing variety of drugs have been developed for 
both prophylaxis and the treatment of venous throm- 
bosis. 14-16 New approaches to deep vein thrombosis 
(such as catheter-directed thrombolysis) may play an 
important role to restore patency in selected patients 
and may prevent long-term sequelae.17 Despite these 
advances, prophylaxis for deep vein thrombosis still 
used infrequently, and patients with established deep 
vein thrombosis are often inadequately treated. 1s,19 
These three clinical examples illustrate the funda- 
mental disparity between the high prevalence of 
vascular diseases (with associated morbidity, disability, 
and mortality) and the underrecognition a d treat- 
ment of vascular diseases by many in the general 
medical community. Although numerous clinical tri- 
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als have clarified the appropriate use of diagnostic and 
therapeutic approaches to vascular diseases, it is not 
lmown how well these data have been applied by pri- 
mary care physicians in the United States. Specific ar- 
eas in which such data would be critically important 
include: (1) the application of carotid artery duplex 
ultrasonography for both asymptomatic and symp- 
tomatic individuals, with improved referral patterns 
for carotid surgery; (2) improved referral patterns for 
iliac artery percutaneous revascularization (both per- 
cutaneous transluminal angioplasty and stents); (3) 
wider application of appropriate lipid-lowering thera- 
pies; and (4) widespread use of supervised exercise 
rehabilitation programs for treatment ofclaudication. 
We believe that a more comprehensive p rspective r - 
garding the diffuse nature of vascular diseases should 
lead to a shift of medical care resources for these pa- 
tients.l.4, 2° 
Patients will also benefit from the development of
the specialty of vascular medicine, which consists of 
internists with spccial expertisc in the diagnosis and 
management of vascular disorders. Growth of this 
clinical discipline will be accelerated by advances in 
vascular biology that are translated into clinical prac- 
tice, and by greater opportunities for clinical and 
research training in vascular discases. In this era of 
cost-containment, the new clinical disciplinc of vas- 
cular medicine will need to document i s utility by 
evaluation of patient satisfaction and outcomes, and 
demonstration f cost-effectiveness. 
The purpose of this article is to describe the role of 
vascular medicine as it relates to contemporary clinical 
care, training, and research in vascular diseases. Our 
thesis is that all vascular care professionals must 
combine their talents and skills to improve the health 
of individuals with vascular disease in a cost-effective 
manner. We are fortunate that previous discussions 
within the various vascular specialties have evolvcd 
rapidly to permit elucidation of specific, common, 
clinically important goals. An effective partnership of 
vascular medical, surgical, and interventional radiol- 
ogy caregivers can realistically deliver such clinical 
promises. This partnership should ultimately encom- 
pass all professional societies that are committed to 
the care of patients with vascular diseases. 
THE EMERGENCE OF 
VASCULAR MEDICINE 
Vascular medicine is defined as the specialty en- 
compassing the medical management of diseases 
that affect the peripheral arteries, veins, lymphatics, 
and the microcirculation. Vascular medicine special- 
ists also evaluate and treat patients with disorders 
that predispose them to vascular diseases uch as 
hypertcnsion, dyslipidemias, diabetes, and coagu- 
lopathies. 
Vascular medicine is not a new medical specialty, 
but is distinct from cardiology and has been repre- 
sented in both academic and private practice institu- 
tions in the United States for more than 40 years. 
Recent advances in vascular biology and a greater 
awareness of the morbidity and mortality of vascular 
diseases have accelerated the growth of vascular medi- 
cine. The mission of vascular medicine is to improve 
patient care, integrate knowledge derived from vas- 
cular biology into clinical practice, and promote 
excellence in training, education, and community 
outreach. This mission is congruent with the mission 
of our colleagues in vascular surgery, intervcntional 
radiology, vascular nursing, and vascular technology. 
Such goals have been pursued for decades by vascular 
internists at a number of national institutions, uch as 
the Mayo Clinic, the Cleveland Clinic, the Lahey 
Clinic, and Boston University. Additional vascular 
medicine programs have recently been created at 
several major universities. Each of these vascular 
medicine centers has established clinical fellowship 
training programs (Appendix I), and provides oppor- 
tunities for the training of both basic scientists and 
clinician-investigators to aid the growth of vascular 
biology and vascular medicine. As might be expected, 
vascular medicine, vascular surgery, and interven- 
tional radiology have grown synergistically at each of 
these institutions. The broad interest in vascular 
diseases has also led to the formation of several 
vascular societies (Appendix II). 
Recently a number of additional factors have 
converged to enhance the growth of vascular medi- 
cine in the 1990s. The National Heart, Lung, and 
Blood Institute of the National Institutes of Health 
(NIH) has galvanized the vascular community by 
instituting the Vascular Disease Academic Awards, 
which has provided initial support for 15 geographi- 
cally diverse vascular centers nationally (Appendix 
III). Developments in vascular biology and growing 
interest in vascular pharmacotherapies have created a
relative proliferation of new investigational gents to 
treat vascular diseases. To foster the continued growth 
of vascular medicine, a national society of vascular 
scientists and clinicians was founded in 1989. The 
Society for Vascular Medicine and Biology was cre- 
ated to represent the clinical, research, and training 
interests of vascular internists. This society has played 
a key role in defining this new specialty and has 
progressively strengthened itsrelationship with other 
established vascular societies. 
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GOALS OF VASCULAR MEDICINE 
Clinical mission. A central mission of vascular 
medicine is to improve the early recognition of 
vascular diseases by the general medical community, 
which should lead to better outcomes for this patient 
population. For example, PAD is highly prevalent, 
with approximately two thirds of patients having 
asymptomatic disease. 3,21 Patients with "silent" PAD 
have a high risk of cardiovascular mortality given their 
associated coronary and cerebrovascular disease. 6 
Screening methods for PAD are readily available with 
the ankle-brachial index, and strategies to modify 
cardiovascular risk factors are well established. There- 
fore it is reasonable to postulate that early detection 
and treatment of PAD will delay the progression of 
the systemic atherosclerosis, thus reducing morbidity, 
disability, cardiovascular mortality, and costs related 
to health care. Whereas vascular internists and vascu- 
lar surgeons share a common interest in improving the 
clinical outcomes of vascular disease, the vascular 
internist is uniquely situated to provide medical 
therapy directed toward risk-factor modification and 
disease prevention. 
A number of regional vascular disease screening 
programs have been established by the Society for 
Vascular Nursing and several vascular internists. 
These programs will determine the local prevalence of 
PAD, improve awareness of vascular disease in the 
community, and document current reatment s rate- 
gies for the disease. The application ofantiatheroscle- 
rosis therapies for PAD has been addressed by the 
NIH with the Arterial Disease Multiple Intervention 
Trial. This is a pilot study to evaluate the effects of 
risk-factor modification, antioxidants, and anticoagu- 
lants on cardiovascular mortality in patients with 
PAD. Other specific antiathcrosclerofic therapies to 
be considered inpatients with PAD include antiplate- 
let agents, lipid-lowering drugs, vitamin therapy to 
reduce homocysteine l vels, and agents that restore 
endothelial nd vascular Function (e.g., modulation of 
nitric oxide synthesis). 
In symptomatic patients with vascular disease, the 
vascular internist is dedicated to providing effective 
medical and pharmacologic therapies. In patients with 
disabling claudication, treatment should include pre- 
scription of a supervised exercise rehabilitation pro- 
gram, which has been well established as a beneficial 
therapy for these patients. All controlled trials of 
exercise treatment for claudication have reported a 
large increase in treadmill exercise performance and 
pain-free walking time during exercise. 2225 After 
completing the supervised program, it is important 
that the patient exercise regularly to maintain benefit. 
From thc patient's perspective, this improvement in
exercise performance is associated with better fimc- 
tioning at work, at home, and during leisure time. s
This consistent finding demonstrates that exercise 
training programs promote a clinically important 
improvement of functional capacity in patients for 
whom other treatment options are limited and in 
whom spontaneous recovery occurs infrequently. In 
addition, exercise training causes virtually no morbid- 
ity or mortality. Thus exercise rehabilitation may be as 
effective as surgery or angioplasty in treating claudi- 
cation, but at a lower morbidity rate and COSt. 22'26 
Pharmacologic therapy for PAD has had limited 
success in improving symptoms of claudication. Sev- 
eral clinical trials currently arc evaluating new drug 
therapies for patients with claudication. Agents that 
improve ischemic skeletal muscle metabolism, novel 
vasodilators, and prostaglandin analogues now are 
being developed. 27,28 When limbs that have claudica- 
tion progress to ischemia, surgical therapy and endo- 
vascular interventions arc the primary and most 
effective treatments in the majority of cases. Many of 
these patients are critically ill, however, and are at high 
risk for cardiovascular events after surgery. Therefore, 
the vascular internist is also committed to developing 
new therapies that may delay the need for surgery in 
these high-risk patients. Prostaglandin analogues, 
antiplatelet agents, and angiogenic factors that stimu- 
late the growth of new vessels are under investigation 
for patients with critical leg ischemia. 29 
A number of other vascular diseases are primarily 
managed without surgery. Raynaud's phenomenon 
often requires specialized vascular testing, and the 
treatment ofvasospasm uses environmental nd phar- 
macologic modifications. Calcium entry blockers, 
sympatholytics, and prostaglandin analogues have 
helped many patients, but a better understanding of
the pathogenesis of the disease will be necessary to 
develop more effective therapies. In patients with 
venous thrombosis, the development ofnew antico- 
agulant drugs and treatment protocols will potentially 
improve outcomes. 16Thrombolytic agents and the 
advent of new modes of catheter-directed delivery at 
the site of the thrombus are examples in which 
collaboration between the vascular internist and our 
surgery and radiology peers will further improve 
overall therapy. 
Most patients with vascular disease are managed 
by primary care physicians. These physicians often 
require consultation with a vascular specialist to 
optimize medical care, but even motivated practitio- 
ners will be increasingly challenged to remain familiar 
with the rapid advances in medical, surgical, and 
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interventional therapy for vascular diseases. These 
physicians will also be under increasing economic 
pressure to minimize the use of surgical and intcrven- 
tional procedures. To address these issues, we propose 
that when the majority of a patient's problems are 
related to the vascular system, the vascular internist 
may become the "principal care" provider, thus 
bridging primary and specialty care. The vascular 
internist would outline appropriate strategies to both 
retard disease progression (including risk-factor 
modification) and improve the symptoms of the 
disease. The vascular internist would also facilitate and 
encourage appropriate referrals to vascular surgeons 
or endovascular intcrventionalists when revascular- 
ization procedures arc needed. This approach is 
critical, because primary care physicians and managed 
care organizations will not support the increasing 
rates of peripheral vascular surgical and interventional 
procedures unless the costs and benefits of these 
procedures can be demonstrated. 3° Thus the vascular 
internist can establish an important link between a
health care system that mandates primary care and 
may impose restrictions on the use of vascular surgical 
and interventional procedures. Such collaboration 
will provide effective medical therapies for patients 
with systemic vascular diseases, optimize vascular 
referral patterns, and reduce health care costs. 
Development ofvascular centers. Realization of 
the ideal to provide comprehensive ascular care now 
exists in the multidisciplinary vascular center. This 
concept has been promoted by funding from the NIH 
with the Vascular Disease Academic Award. These 
centers include practitioners from vascular medicine, 
vascular surgery, interventional radiology, and vascu- 
lar nursing. The vascular center is supported by a 
comprehensive ascular laboratory and a database to 
facilitate outcome analyses and clinical studies. Re- 
lated medical expertise in the vascular center may 
include expert specialists in the areas of coagulation 
disorders, lipid metabolism, foot and wound care, 
vascular disease, and pulmonary and renovascular 
hypertension. Communication among these special- 
ties is critical to the optimal functioning of the vascular 
center. Costs will be reduced ifmedical therapies and 
risk-factor modification can retard the progression of 
vascular disease. Effective medical therapies (e.g., 
exercise rehabilitation for claudication) may also de- 
crease the need for surgical treatments until patients 
progress to more advanced stages of vascular disease. 
Thus, the vascular center becomes an efficient means 
to provide the most current and comprehensive 
diagnosis and treatment strategies for patients with 
peripheral vascular diseases. 
Educational mission. Clinical care of vascular 
disease is enhanced by programs that inform the 
public, primary care practitioners, and trainees. Vas- 
cular surgery, interventional radiology and vascular 
nursing communities have effectively promoted this 
mission, yet much more remains to be accomplished. 
Vascular internists are committed to training medical 
students, residents, and fellows in internal medicine, 
surgery, radiology, and pathology. The interaction 
with cardiology training programs is particularly im- 
portant in areas uch as the preoperative evaluation of 
vascular surgical patients to expedite these patients to 
surgery. Guidelines must reflect recent data that a 
more limited cardiac work-up before vascular surgery 
may actually decrease overall morbidity and costs. 31 
Comprehensive training in all clinical aspects of vas- 
cular disease is also necessary for physicians who 
undertal~e endovascular interventions. 
Several vascular centers across the United States 
have developed vascular medicine fellowship pro- 
grams (Appendix I). The goal of these fellowships i to 
provide training for physicians in the comprehensive 
evaluation and treatment of peripheral vascular dis- 
eases. Yet fellowship training in vascular medicine is 
still in development, and no federal source of funding 
yet exists for vascular fellows. An important goal of the 
Society for Vascular Medicine and Biology is to 
develop additional funding mechanisms to improve 
and enhance fellowship training. 
Since the Society for Vascular Medicine and Biol- 
ogy was founded, its leadership has emphasized the 
critical importance of improving the scientific and 
clinical content of educational materials presented to 
medical students, fellows, and practicing physicians. 
Since 1991, the Society for Vascular Medicine and 
Biology has established and coordinated an increasing 
number of vascular disease courses for primary care 
physicians. Educational symposia that focus on vas- 
cular disease have been welcomed at the annual 
Scientific Sessions of the American College of Physi- 
cians, the annual meeting of the Society of General 
Internal Medicine, at NIH symposia, and numerous 
regional forums. The Society for Vascular Medicine 
and Biology offers to educators from all specialties an 
opportunity to seek societal sponsorship of regional 
or national courses. Such sponsorship is provided to 
vascular educational symposia that encompass a mul- 
tidisciplinary perspective and maintain high standards 
of content. As an example, the Society for Vascular 
Medicine and Biology sponsored the first interna- 
tional symposium on "The Pharmacotherapy of Clau- 
dication" in May 1995, in Washington, D.C. This 
meeting included an esteemed international nd in- 
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Table I. Potential areas for intersocietal 
liasions to improve vascular care practices 
Encourage interdisciplinary dialogue at educational con- 
ferences 
Promote cross-disciplinary vascular fellowship training 
Collaborate in multicenter t ials 
Increase community awareness of the importance of vas- 
cular diseases 
Foster vascular disease advocacy groups 
Promote the development ofvascular centers 
terdisciplinary faculty who provided information on 
recent advances in the medical therapy of clandica- 
tion. The meeting also resulted in several recommen- 
dations for the development of interventions to 
favorably affect he natural history of PAD and treat 
clandication. 
An important outcome of educational programs 
in vascular diseases i to optimize referrals from pri- 
mary care physicians into vascular centers. Through 
our efforts at continuing medical education, we hope 
to increase the early recognition of common vascular 
diseases among primary care physicians. It is critical 
that these physicians appreciate he pathophysiology, 
natural history, and treatment of vascular diseases to 
facilitate appropriate r ferrals to vascular specialists. 
Vascular esearch mission. Advances in vascular 
biology in the past decade have shed new light on the 
mechanisms bywhich the vessel wall controls its tone, 
growth, and interaction with circulating blood ele- 
ments. Insights have been gained regarding the dis- 
turbances of vascular homeostasis that cause vascular 
disease, and advances in vascular biology are likely to 
lead to novel therapies. 32,33 Research in vascular biol- 
ogy has been greatly facilitated by the NIH program 
project grants in vascular biology and medicine. 
Recent advances to treat vascular disease include 
gene therapy. This approach was derived from bench 
research, was initially applied in animal models of 
vascular disease, and has now reached preliminary 
human clinical trials. Catheter-directed administra- 
tion of genes that encode angiogenic factors are 
currently being used to enhance the development of
the collateral circulation in patients with pAD.29 
Other frontiers of gene therapy include the develop- 
ment of antisense oligonucleotides directed against 
nuclear proteins that are required for the cell cycle. In 
animal models, these oligonucleotides inhibit myoin- 
timal hyperplasia fter balloon angioplasty orvenous 
bypass grafting? 3,34 Gene transfer techniques have 
successfully restored elaboration of endogenous va- 
sodilators after vascular injury in animal models of 
disease. 35 Many novel treatments will develop from 
new knowledge regarding the pathobiology of ath- 
erosclerosis and restenosis and an improved under- 
standing of the factors that promote plaque rupture. 
Vascular biologists are generating new insights 
regarding the role of apoptosis in vascular emodel- 
ing, the principles of vascular adhesion biology, the 
transduction ofhumoral and hemodynamic stimuli, 
• concepts regarding the elaboration and degradation 
ofextracellular matrix, lipoproteins and their interac- 
tion with the vessel wall, and cellular and molecular 
mechanisms ofthrombosis and fibrinolysis. 
Vascular medicine physicians and vascular sur- 
geons are ideally positioned to translate advances in 
vascular biology into clinical practice. This has led to 
clinical trials of new pharmacologic agents in the 
treatment ofclaudication that will test the efficacy of 
drugs that promote regional vasodilation, lower vis- 
cosity, improve skeletal muscle metabolism, and pro- 
mote angiogenesis.27,29 Critical in the development of 
clinical trials has been a reevaluation fthe guidelines 
for conducting such trials, including recommenda- 
tions for graded treadmill testing and a battery of 
questionnaires to assess treatment effect in patients 
with claudication. 36 
OUTCOMES OF A PARTNERSHIP 
BETWEEN THE VASCULAR SPECIALTIES 
Although it is difficult o speculate on the future 
impact of vascular medicine on surgical or interven- 
tional treatments for vascular disease, successful medi- 
cal therapies may modify the need for some invasive 
therapies. In patients with claudication, effective 
medical therapies may reduce the future rates of an- 
gioplasty and surgery. Prostaglandin drugs and anglo- 
genie growth factors may delay the need for surgery in 
critical eg ischemia, particularly inhigh-risk patients. 
Vascular internists, however, are also more likely to 
refer patients to vascular surgeons for definitive inter- 
ventions that are currently underused. Recent studies 
on the treatment of asymptomatic carotid stenosis 
support he increased use of carotid endarterectomy 
in the treatment ofselected patients. ~1 The results of 
ongoing clinical trials may ultimately increase the use 
of surgical treatment for small abdominal ortic aneu- 
rysms. The integration of vascular medicine, vascular 
surgery, and interventional radiology in the vascular 
center will help to coordinate appropriate referrals 
and use of surgical therapies to treat vascular diseases. 
Therefore, vascular medicine, surgery and radiology 
are closely allied in a common mission to provide op- 
timal care for patients with vascular diseases. A sum- 
mary of these and other potential areas of interaction 
are listed in Table I. 
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Although progress has been made in the estab- 
l ishment of vascular medicine, we have not  yet 
reached a critical mass of vascular practitioners to 
completely realize our clinical, educational, and re- 
search goals. In  Europe and the Uni ted States, the 
integration of angiology and vascular medicine with 
vascular surgery should lead to better surgical referral 
patterns and improved care of patients with vascular 
diseases. 
CONCLUSION 
The primary mission of the vascular medicine 
specialist is to provide optimal medical care for 
individuals with vascular diseases. This mission is 
facilitated by our vascular educational curricula nd by 
applying advances from vascular research into clinical 
medicine. These goals are congruent  with those of 
our vascular surgery and interventional radiology 
colleagues. A partnership in achieving these clinical, 
educational, and research missions is likely to result in 
benefit for the practitioner and the patient alike. 
We thank Frank Veith, MD, for his helpful comments 
on the manuscript. 
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